Abstract
Nausea and emesis are common side effects of gastrointestinal disease. Reports indicate that ghrelin and endocannabinoids, agents that stimulate appetite, also reduce emesis evoked by chemotherapy treatment, which suggests that stimulation of feeding inhibits the emetic system. In the following study we conducted a more direct test of this hypothesis by determining the impact of manipulating the motivation to eat on emesis, using food restriction and refeeding. Emesis was induced in musk shrews, a commonly used animal model for emesis research, using the cancer chemotherapy agent cisplatin (20 mg/kg ip), nicotine (2 mg/kg sc), or motion (1 Hz, horizontal, 4-cm displacement), because these treatments are known to target separate emetic pathways: gut vagal afferents, area postrema, and vestibular pathways, respectively. Twenty-four hours of food restriction was sufficient to stimulate food intake, and 1 h of refeeding filled the stomach. The results indicate that food restriction, refeeding, and gastric fill had no significant effects on the amount of emesis produced by any of the emetic treatments tested here. This suggests that, although activation of the emetic system might have prominent effects on food intake, neural controls for feeding behavior do not significantly affect the neural pathways for emesis. These results may have implications for how we treat patients who experience a constellation of side effects, including nausea and emesis, since stimulating appetite may not necessarily inhibit emetic pathways.
Keywords: nausea, emesis, vagus, cisplatin
translational highlights Reports suggest that stimulating appetite using drugs might reduce vomiting evoked by cancer chemotherapy treatment. The present study shows that stimulating appetite, by use of food restriction, and refeeding in musk shrews does not affect emesis induced by a variety of stimuli, including chemotherapy. These results may have implications for how we treat patients who experience side effects, including nausea and emesis produced by chemotherapy.
The primary function of nausea and vomiting is to defend against the ingestion of toxins. Vomiting empties toxins from the gut, and, arguably, nausea can serve as a learned response that prevents the future ingestion of toxins (14). Many diseases and conditions, as well as their treatments, cause nausea and vomiting (emesis) (26). Severe and prolonged emesis can affect patients' nutritional health, quality of life, and willingness to continue treatments that include nausea and vomiting as prominent side effects. It is more difficult to treat nausea than emesis, and our understanding of the biology of nausea is limited because it is difficult to assess nausea in animal models (5, 26).
Although of great benefit, antiemetic drugs are not always effective for controlling emesis (e.g., Ref. 1) and often are not adequate for reducing nausea (13). It would be beneficial to find other approaches or adjunctive methods to control nausea and vomiting. Appetite and nutritional factors are sometimes cited as variables that influence the degree of nausea and vomiting (e.g., Ref. 7). Clinical evaluations tend to link appetite with nausea and emesis; for example, the grading of nausea used by the National Cancer Institute (9) in clinical trials is sometimes related to the amount of reduced appetite. In a converse fashion, administration of appetite stimulants, such as cannabinoids and ghrelin (10, 36), inhibits emesis in ferrets and least shrews (22, 24, 33). This suggests that activation of neural systems controlling appetite inhibit emesis, perhaps by stimulating a competitive response (feeding) to vomiting.
As a first step toward evaluating the potential impact that feeding may have on emesis we studied musk shrews, a well-established model of emesis (16, 19, 32). To expand on the findings that cannabinoids and ghrelin inhibit emesis, we sought to determine whether fasting, a natural stimulus for feeding and subsequent refeeding (sufficient to fill the stomach) would modify emesis induced by activation of different neural pathways: gut vagal afferents (using the cancer chemotherapy agent cisplatin) (4, 19), the area postrema (using nicotine) (6, 32), and the vestibular system (using horizontal motion) (16). Our initial work used musk shrews originally derived from Guam. However, we discovered that this Guam strain was insensitive to motion-induced emesis, so we completed our studies using a Taiwan strain known to show a potent emetic response to motion (e.g., Refs. 2, 8, 16, 31).
METHODS
Subjects.
Studies were performed on adult (>40 days of age) male musk shrews (Suncus murinus). Shrew colonies were created from stock obtained from Dr. Emilie Rissman at the University of Virginia (descendents from animals originally collected in Guam) (e.g., Ref. 35) and Dr. John Rudd at the Chinese University of Hong Kong (descendants from Taiwan) (23, 34). Sixty-two Guam-derived shrews (mean = 37.9 ± 0.6 g, range = 29.4–49.6 g) and 104 Taiwan-derived shrews (mean = 64.5 ± 0.8 g, range = 38.7–88.9 g) were used. Shrews were housed individually in a temperature-controlled vivarium with a 12:12-h light-dark cycle (0700–1900 light period) and ad libitum access to tap water and food [mixture of 75% Purina Cat Chow Complete Formula and 25% Complete Gro-Fur mink food pellets (Milk Specialty, New Holstein, WI)], except as indicated. This protocol was approved by the Monell Chemical Senses Center Institutional Animal Care and Use Committee.
Food intake.
To determine the length of fasting required to significantly stimulate appetite, we fasted animals for 3 and 24 h. Two separate food intake studies (using within-subjects designs), one with Guam-derived shrews (n = 4) and another with Taiwan-derived shrews (n = 8), were conducted. Initially, half the animals were fed ad libitum and half were fasted for 3 h. For the 3-h fasted condition, food was removed at ∼0900 and returned at ∼1200. Food was weighed at 0, 1, 2, and 3 h starting at ∼1200. At least 2 days later, the group assignment was reversed and the experiment was repeated. At least 3 days after the second feeding test, the same animals were retested under ad libitum feeding or 24-h fasting conditions (food removed at ∼1200 the prior day and tested at ∼1200), and treatments were reversed at least 3 days later.
Gastric emptying and body weight.
To determine the impact of refeeding on stomach fill we fasted animals for 24 h and refed for 1 h and weighed the stomach contents. We also included ad libitum-fed, 3-h fasted, and 24-h fasted conditions for comparison. Separate gastric emptying studies using Guam-derived and Taiwan-derived shrews were conducted. Musk shrews were housed under four conditions: ad libitum access to food, 3-h fasted, 24-h fasted, and 24-h fasted plus 1-h refed (n = 6 per condition) and were then euthanized (∼1200) with an overdose of pentobarbital sodium (25 mg, 0.5 ml ip). Body weight for the shrews was determined, and then the contents of the stomach and the first 10 cm of intestine were weighed (wet weight) and then dried in an oven overnight to determine dry weight. In the second study, using Taiwan-derived shrews, we also measured the remaining portion of the intestinal contents. This extended segment of the intestine was of variable length (25–36 cm).
Emesis.
Three stimuli known to reliably produce emesis in musk shrews (e.g., Refs. 16, 19, 27) were used: cisplatin (20 mg/kg ip; Sigma-Aldrich, cis-diamineplatinum dichloride, no. P4394), nicotine [2 mg/kg sc; Sigma-Aldrich, (−)-nicotine, no. 36733], and motion (1 Hz, 4 cm horizontal, 10 min with reciprocal shaker; see below). Cisplatin and nicotine were prepared in physiological saline (0.9% NaCl). Cisplatin was injected intraperitoneally in a volume of 10 ml/kg body wt, and nicotine was administered subcutaneously in a volume of 2 ml/kg body wt. Immediately after injection, animals were placed into a clear plastic container (28 × 17 × 12 cm) without food or water, and a trained observer recorded the timing and number of emetic responses for 120 min for cisplatin tests and for 30 min for nicotine tests.
For motion experiments, animals were placed individually in a clear plastic container (28 × 17 × 12 cm) on a reciprocal shaker (Taitec, Double Shaker R-30, Taiyo Scientific Industrial). Animals were allowed 3 min to acclimate before the shaker was turned on. Horizontal motion continued for 10 min with 4-cm displacement (2 cm left, 2 cm right) at a frequency of 1 Hz. Observation was continued for 5 min after the shaker was turned off. These parameters for motion exposure were determined by past studies to be optimal for inducing emesis in musk shrews (16).
Emetic responses were defined as a short burst of retches (∼4 s−1) (3) that occurred with or without expulsion of material from the mouth (vomiting). Each animal was used only once in each emesis test. Tests were run with an equal number of control animals; for example, when two animals fasted for 24 h were tested for emesis after nicotine injection, two additional animals fed ad libitum were tested at the same time. The numbers of animals used in each condition is noted in the figures (n = 5–6 per condition). Animals were tested with cisplatin and nicotine at ∼1200 and for motion exposure at ∼1500. Initial studies used Guam-derived or Taiwan-derived shrews tested with ad libitum feeding or 24-h fasting. A final experiment was conducted with Taiwan-derived shrews to compare ad libitum feeding with 24-h fasting and 1 h of refeeding.
Statistical analysis.
Food intake was analyzed with a 2 × 3 analysis of variance (ANOVA) using level of deprivation (ad libitum and food restriction) and time of refeeding (1, 2, and 3 h) as factors. Planned comparisons were conducted to compare the ad libitum-fed and food-restricted conditions at each time point. Gastric emptying data were analyzed by ANOVA for each segment of the gastrointestinal tract. Planned comparisons were conducted to compare individual means to the ad libitum condition. The number of emetic episodes (retching sequences with or without expulsion) was analyzed via a two-tailed t-test. Emetic episodes with an expulsion (vomits) and without expulsion (retches) are also shown in the figures. Mann-Whitney U-tests were used to compare the medians for response latency to the first emetic episode. For all analyses, SigmaPlot, version 11 (Systat Software) was used, and P < 0.05 was considered statistically significant. Values are reported as means ± SE.
RESULTS
Food intake.
Twenty-four hours, but not 3 h, of food restriction stimulated food intake in Guam-derived and Taiwan-derived musk shrews [no significant effects for the 3-h studies; main effect of food restriction in Guam-derived shrews with 24-h food restriction, F(1,23) = 13.5, P < 0.05; interaction effect of food restriction and time in Taiwan-derived shrews with 24-h food restriction, F(2,47) = 14.2, P < 0.001; Fig. 1 ]. The increase in food intake after 24-h food restriction was seen at 0–1 h and 2–3 h in both Guam- and Taiwan-derived shrews compared with ad libitum-fed animals (Fig. 1; planned comparisons, P values < 0.05).
Fig. 1.
Food intake 3 h after 3-h fast (top) or 24-h fast (bottom) in Guam- and Taiwan-derived musk shrews, compared with ad libitum food intake. *P < 0.05, planned comparison, ad libitum vs. fasted condition at a specific time period. Data are means + SE.
Gastric emptying and body weight changes after fasting.
Compared with ad libitum-fed controls, both types of shrew fasted for 24 h and refed for 1 h had significantly more wet and dry stomach contents [one-way ANOVAs, Fs(2 or 3,23) ≥ 7.0, Ps < 0.005; planned comparisons, P values < 0.05; Fig. 2 ]. There were no statistically significant differences in the contents of the first 10 cm of the intestine (ANOVAs or planned comparisons; Fig. 2). However, the Taiwan-derived shrews showed a significant increase in weight of contents of the extended intestine, both wet and dry, in the 24-h fast plus 1-h refed group compared with ad libitum control animals [one-way ANOVAs, Fs(3,23) ≥ 3.6, Ps < 0.05; planned comparisons, P values < 0.05; Fig. 2].
Fig. 2.
Gastric and intestinal contents after fasting and refeeding in Guam- and Taiwan-derived musk shrews. Animals were fed ad libitum, fasted for 3 h, fasted for 24 h, or fasted for 24 h and refed for 1 h. Data represent the mean + SE of wet and dry contents of the stomach, intestine (10 cm starting at the pyloric sphincter), or extended (ext.) intestine (remaining intestinal segment, ∼30 cm). *P < 0.05, planned comparison, a specific group vs. the ad libitum-fed group.
In Guam-derived shrews, 3 h of fasting reduced body weight by 2% [prefast, 38.8 ± 2.5 g, vs. postfast, 37.9 ± 2.5 g; t(5) = 5.8, P < 0.005, two-tailed], and 24 h of fasting reduced it by 12% [prefast, 39.7 ± 2.3 g, vs. postfast, 35.1 ± 2.4 g; t(5) = 11.0, P < 0.001, two-tailed]. Animals fasted for 24 h with 1 h of refeeding ate 0.52 ± 0.16 g of food and lost 13% of body weight [prefast, 39.2 ± 2.1, vs. postrefed, 34.0 ± 1.8 g; t(5) = 11.4, P < 0.001, two-tailed].
In Taiwan-derived shrews, 3 h of fasting reduced body weight by 4% [prefast, 76.4 ± 4.0 g, vs. postfast, 73.6 ± 3.9 g; t(5) = 4.8, P < 0.01, two-tailed] and 24 h of fasting reduced it by 10% [prefast, 68.3 ± 2.8 g, vs. postfast, 61.5 ± 2.4 g; t(5) = 16.5, P < 0.001, two-tailed]. Animals fasted for 24 h with 1 h of refeeding ate 1.4 ± 0.0 g of food and lost 8% of body weight [prefast, 65.0 ± 2.3, vs. postrefed, 59.8 ± 2.0 g; t(5) = 17.1, P < 0.001, two-tailed].
Emesis after fasting.
There were no statistically significant differences between ad libitum-fed or 24-h-fasted animals in the amount of emetic episodes or in latency for emesis after treatment with cisplatin, nicotine, or motion exposure (see Figs. 3–5; t-tests for number of emetic episodes or Mann-Whitney U-tests for emetic response latency). The results for cisplatin and nicotine were the same for Guam- and Taiwan-derived shrews; Guam-derived shrews did not show emetic responses to motion (Fig. 5).
Fig. 3.
Emetic responses to cisplatin treatment after 24 h of fasting in Guam- and Taiwan-derived musk shrews. Top: number of emetic episodes: vomits (emetic episodes with expulsion) and retches (emetic episodes without expulsion). Numbers above each bar are n responders/n animals tested. Data are means + SE. Bottom: latency to the first emetic response (the maximum time for the observation period was used if an animal did not respond). Data are median latency and a scatterplot of each value.
Fig. 4.
Emetic responses to nicotine treatment after 24 h of fasting in Guam- and Taiwan-derived musk shrews. Top: number of emetic episodes: vomits (emetic episodes with expulsion) and retches (emetic episodes without expulsion). Numbers above each bar are n responders/n animals tested. Data are means + SE. Bottom: latency to the first emetic response (the maximum time for the observation period was used if an animal did not respond). Data are median latency and a scatterplot of each value.
Fig. 5.
Emetic responses to motion exposure after 24 h of fasting in Guam- and Taiwan-derived musk shrews. Top: number of emetic episodes: vomits (emetic episodes with expulsion) and retches (emetic episodes without expulsion). Numbers above each bar are n responders/n animals tested. Data are means + SE. Bottom: latency to the first emetic response (the maximum time for the observation period was used if an animal did not respond). Data are median latency and a scatterplot of each value.
Emesis after fasting and refeeding.
Taiwan-derived shrews showed no effects of refeeding for 1 h after a 24-h fast on emetic responses produced by cisplatin, nicotine, or motion compared with ad libitum-fed animals (t-tests for number of emetic episodes or Mann-Whitney U-tests for emetic response latency; Fig. 6). During refeeding, food-restricted animals ate 1.7 ± 0.7, 1.1 ± 0.2, and 1.6 ± 0.3 g of food in the cisplatin, nicotine, and motion studies, respectively.
Fig. 6.
Emetic responses to cisplatin, nicotine, and motion exposure after 24 h of fasting plus 1 h of refeeding in Taiwan-derived musk shrews. Top: number of emetic episodes: vomits (emetic episodes with expulsion) and retches (emetic episodes without expulsion). Numbers above each bar are n responders/n animals tested. Data are means + SE. Bottom: latency to the first emetic response (the maximum time for the observation period was used if an animal did not respond). Data are median latency and a scatterplot of each value.
DISCUSSION
The present results show that in musk shrews neither food restriction, food intake, nor gastric fill have significant effects on emesis produced by a variety emetic stimuli. Our initial hypothesis was that fasting would reduce emesis because an increase in appetite for food can be viewed as a competing response to emesis. Endocannabinoids and ghrelin, which are well-known stimulants of food intake (10, 36), also reduce cisplatin-induced emesis in the ferret and least shrew (22, 24, 33). Similar to effects observed in rodents, ghrelin is present in the gastrointestinal tract of the musk shrew and endocannabinoids have been measured in the brain of the least shrew (11, 15). In rodents, fasting increases plasma levels of ghrelin and brain levels of endocannabinoids (12, 28), which suggests that similar changes might occur in musk shrews. However, we found no significant effects of food restriction and feeding on emesis produced by cisplatin or other emetic treatments. This is evidence that, although activation of emesis decreases appetite and eating (e.g., patients with bouts of vomiting and sustained nausea are unlikely to eat), the reverse does not appear to be true: a change in appetite does not directly affect emesis. From this perspective, it also appears that the antiemetic effect of cannabinoids or ghrelin is unrelated to their actions on feeding behavior or that the mechanisms that trigger eating behavior after administration of these agents are different from those involved in feeding induced by fasting. The present study also shows that the amount and latency for emesis is not affected by gastric fill. A 24-h fast emptied the stomach and refeeding filled the stomach, but neither condition affected emesis produced by any of the emetic stimuli.
Motion exposure produced no emesis in these Guam-derived shrews. In fact, we are unaware of any reports of motion-induced emesis in this strain of musk shrew. However, this response is not completely absent in Guam shrews since we have observed a few animals with motion-induced emesis in our colony (C. C. Horn, unpublished data). On the other hand, not all Taiwan-derived shrews display motion-induced emesis. In the present study, only ∼58% of Taiwan-derived shrews showed motion-induced emesis, and not all shrews of this strain showed emesis to motion exposure in studies reported in the literature (e.g., Refs. 20, 23). It is possible that some shrews might be sensitive to motion-induced emesis under different parameters (e.g., a higher frequency of shaking) than those used here and in other studies (16).
Our results indicate that neither fasting nor refeeding has a significant effect on emesis. Five to six musk shrews were used in each of the present experiments, comparable to group sizes used in other studies on the pharmacology of emesis in musk shrews (e.g., Refs. 23, 25). Although the use of larger sample sizes might show statistically significant effects, the present data suggest that any effects that may be uncovered would be modest and not equivalent to the magnitude of effects produced by known antiemetic treatments, including 5-HT3 and NK1 receptor antagonists (e.g., Refs. 23, 25). This information might be useful when considering how to reduce emesis in patients who receive treatments like cancer chemotherapy that produce strong effects of emesis and nausea (17). Some reports have suggested that food restriction might protect against the side effects of chemotherapy because food restriction reduces oxidative stress (21). In line with this idea are data pointing to a role for increased oxidative stress as a mediator of chemotherapy-induced emesis (e.g., Refs. 18, 29, 30). However, the present data indicate that the amount of emesis is not significantly affected by food intake or nutritional status before chemotherapy treatment, which therefore will likely prove to be an insignificant factor for the control of chemotherapy-induced emesis. Whether fasting prior to chemotherapy is a useful adjunctive treatment for emesis and nausea remains to be seen.
GRANTS
This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK065971). Publication costs were funded by the University of Pittsburgh Cancer Institute, Biobehavioral Medicine in Oncology Program.
DISCLOSURES
No conflicts of interest are declared by the author(s).
ACKNOWLEDGMENTS
We thank Matthew Rosazza for assistance in data collection. We thank Dr. Emilie Rissman, University of Virginia, and Dr. John Rudd, Chinese University of Hong Kong, for supplying the animals used to create the musk shrew colony. We also thank Dr. Paul Andrews, St. George's University of London, for providing the shaker for studies of motion-induced emesis.
REFERENCES
- 1.Aapro MS. How do we manage patients with refractory or breakthrough emesis? Support Care Cancer 10: 106–109, 2002 [DOI] [PubMed] [Google Scholar]
- 2.Andrews P, Dovey E, Hockaday J, Hoyle CH, Woods AJ, Matsuki N. The development of the emetic reflex in the house musk shrew, Suncus murinus. Brain Res Dev Brain Res 121: 29–34, 2000 [DOI] [PubMed] [Google Scholar]
- 3.Andrews P, Torii Y, Saito H, Matsuki N. The pharmacology of the emetic response to upper gastrointestinal tract stimulation in Suncus murinus. Eur J Pharmacol 307: 305–313, 1996 [DOI] [PubMed] [Google Scholar]
- 4.Andrews PL, Davis CJ, Bingham S, Davidson HI, Hawthorn J, Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 68: 325–345, 1990 [DOI] [PubMed] [Google Scholar]
- 5.Andrews PL, Horn CC. Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton Neurosci 125: 100–115, 2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Beleslin DB, Krstic SK, Dozic S. Central nicotinic receptors: vomiting, ear twitching and panting. Brain Res Bull 11: 299–302, 1983 [DOI] [PubMed] [Google Scholar]
- 7.Bischoff SC, Renzer C. Nausea and nutrition. Auton Neurosci 129: 22–27, 2006 [DOI] [PubMed] [Google Scholar]
- 8.Chan SW, Rudd JA, Lin G, Li P. Action of anti-tussive drugs on the emetic reflex of Suncus murinus (house musk shrew). Eur J Pharmacol 559: 196–201, 2007 [DOI] [PubMed] [Google Scholar]
- 9.Common terminology criteria for adverse events (C.T.C.A.E.), Version 4.0 Bethesda, MD: National Cancer Institute, 2009 [Google Scholar]
- 10.Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, Pagotto U. Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 27: 289–301, 2003 [DOI] [PubMed] [Google Scholar]
- 11.Darmani NA, McClanahan BA, Trinh C, Petrosino S, Valenti M, Di Marzo V. Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology 49: 502–513, 2005 [DOI] [PubMed] [Google Scholar]
- 12.Hanus L, Avraham Y, Ben-Shushan D, Zolotarev O, Berry EM, Mechoulam R. Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Res 983: 144–151, 2003 [DOI] [PubMed] [Google Scholar]
- 13.Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 358: 2482–2494, 2008 [DOI] [PubMed] [Google Scholar]
- 14.Horn CC. Why is the neurobiology of nausea and vomiting so important? Appetite 50: 430–434, 2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Ishida Y, Sakahara S, Tsutsui C, Kaiya H, Sakata I, Oda S, Sakai T. Identification of ghrelin in the house musk shrew (Suncus murinus): cDNA cloning, peptide purification and tissue distribution. Peptides 30: 982–990, 2009 [DOI] [PubMed] [Google Scholar]
- 16.Javid FA, Naylor RJ. Variables of movement amplitude and frequency in the development of motion sickness in Suncus murinus. Pharmacol Biochem Behav 64: 115–122, 1999 [DOI] [PubMed] [Google Scholar]
- 17.Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24: 2932–2947, 2006 [DOI] [PubMed] [Google Scholar]
- 18.Matsuki N, Torii Y, Saito H. Effects of iron and deferoxamine on cisplatin-induced emesis: further evidence for the role of free radicals. Eur J Pharmacol 248: 329–331, 1993 [DOI] [PubMed] [Google Scholar]
- 19.Matsuki N, Ueno S, Kaji T, Ishihara A, Wang CH, Saito H. Emesis induced by cancer chemotherapeutic agents in the Suncus murinus: a new experimental model. Jpn J Pharmacol 48: 303–306, 1988 [DOI] [PubMed] [Google Scholar]
- 20.Matsuki N, Wang CH, Okada F, Tamura M, Ikegaya Y, Lin SC, Hsu YN, Chaung LJ, Chen SJ, Saito H. Male/female differences in drug-induced emesis and motion sickness in Suncus murinus. Pharmacol Biochem Behav 57: 721–725, 1997 [DOI] [PubMed] [Google Scholar]
- 21.Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, Longo VD. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci USA 105: 8215–8220, 2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ray AP, Griggs L, Darmani NA. Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew. Behav Brain Res 196: 30–36, 2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Rudd JA, Ngan MP, Wai MK. Inhibition of emesis by tachykinin NK1 receptor antagonists in Suncus murinus (house musk shrew). Eur J Pharmacol 366: 243–252, 1999 [DOI] [PubMed] [Google Scholar]
- 24.Rudd JA, Ngan MP, Wai MK, King AG, Witherington J, Andrews PL, Sanger GJ. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 392: 79–83, 2006 [DOI] [PubMed] [Google Scholar]
- 25.Sam TS, Cheng JT, Johnston KD, Kan KK, Ngan MP, Rudd JA, Wai MK, Yeung JH. Action of 5-HT3 receptor antagonists and dexamethasone to modify cisplatin-induced emesis in Suncus murinus (house musk shrew). Eur J Pharmacol 472: 135–145, 2003 [DOI] [PubMed] [Google Scholar]
- 26.Sanger GJ, Andrews PL. Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci 129: 3–16, 2006 [DOI] [PubMed] [Google Scholar]
- 27.Smith JE, Friedman MI, Andrews PL. Conditioned food aversion in Suncus murinus (house musk shrew) — a new model for the study of nausea in a species with an emetic reflex. Physiol Behav 73: 593–598, 2001 [DOI] [PubMed] [Google Scholar]
- 28.Taleux N, De Potter I, Deransart C, Lacraz G, Favier R, Leverve XM, Hue L, Guigas B. Lack of starvation-induced activation of AMP-activated protein kinase in the hypothalamus of the Lou/C rats resistant to obesity. Int J Obes (Lond) 32: 639–647, 2008 [DOI] [PubMed] [Google Scholar]
- 29.Torii Y, Mutoh M, Saito H, Matsuki N. Involvement of free radicals in cisplatin-induced emesis in Suncus murinus. Eur J Pharmacol 248: 131–135, 1993 [DOI] [PubMed] [Google Scholar]
- 30.Torii Y, Saito H, Matsuki N. Induction of emesis in Suncus murinus by pyrogallol, a generator of free radicals. Br J Pharmacol 111: 431–434, 1994 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Ueno S, Matsuki N, Saito H. Suncus murinus as a new experimental model for motion sickness. Life Sci 43: 413–420, 1988 [DOI] [PubMed] [Google Scholar]
- 32.Ueno S, Matsuki N, Saito H. Suncus murinus: a new experimental model in emesis research. Life Sci 41: 513–518, 1987 [DOI] [PubMed] [Google Scholar]
- 33.Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, Sharkey KA. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121: 767–774, 2001 [DOI] [PubMed] [Google Scholar]
- 34.Wang CH. Introduction: a new experimental animal, Suncus murinus. In: Proceeding of ROC-Japan Symposium on Suncus murinus: New Experimental Animal, Its Speciality and Usefulness, edited by Saito H, Wang CH, Chen CY. Tainan, Taiwan, R. O. C.: Chia Nan Junior College of Pharmacy Press; (Chia Nan, Taiwan ROC), 1994 [Google Scholar]
- 35.Wayne NL, Rissman EF. Effects of photoperiod and social variables on reproduction and growth in the male musk shrew (Suncus murinus). J Reprod Fertil 89: 707–715, 1990 [DOI] [PubMed] [Google Scholar]
- 36.Williams DL, Cummings DE. Regulation of ghrelin in physiologic and pathophysiologic states. J Nutr 135: 1320–1325, 2005 [DOI] [PubMed] [Google Scholar]






